ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, is pleased to announce the admission today of its ordinary shares to trading on the Taipei Exchange.
ASLAN has raised a total of NT$1 billion ($33 million) from the initial public offering.
Carl Firth, CEO of ASLAN Pharmaceuticals, said: “This is a pivotal moment in ASLAN’s evolution. The success of the IPO will enable ASLAN to deliver against its development strategy and plans for growth from a position of financial strength. We look forward to our future as a quoted company with confidence.”
ASLAN currently has a pipeline of five novel compounds and one modybodies platform, focusing on the treatment of Asia-prevalent tumours.
Its lead asset, varlitinib, has commenced a global pivotal study in biliary tract cancer following the Investigational New Drug approval from the US Food & Drug Administration.
Led by a team of highly experienced industry veterans with a strong track record in clinical development, ASLAN has been able to generate revenues through two outlicensing deals, attract international institutional investors, and forge strong partnerships with world-leading research institutions and international biopharmaceutical companies.
